Skip to main content
. 2023 Jun 1;10:1081762. doi: 10.3389/fmolb.2023.1081762

FIGURE 1.

FIGURE 1

Correlation between NLR and outcomes of AGC patients receiving PD-1 antibody-based therapy. (A) NLR-T2 and patients’ objective response; (B) NLR-T1 and patients’ objective response; (C) NLR-T0 and patients’ objective response; (D) patients with high NLR-T1 had poorer PFS than those with low NLR-T1; and (E) patients with high NLR-T2 had poorer PFS than those with low NLR-T2.